CN Patent

CN105496970A — 含有利格列汀的组合物及其制备方法

Assigned to BEIJING HUAXI PHARM Co Ltd · Expires 2016-04-20 · 10y expired

What this patent protects

DDP-4抑制剂利格列汀用于治疗II型糖尿病，但其在水中溶解度极低(0.9mg/ml)。本发明公开了一种含有利格列汀的药物组合物及其制备方法，利用该工艺得到的组合物制备成可接受的药物剂型，能够明显的改善利格列汀的溶出度。

USPTO Abstract

DDP-4抑制剂利格列汀用于治疗II型糖尿病，但其在水中溶解度极低(0.9mg/ml)。本发明公开了一种含有利格列汀的药物组合物及其制备方法，利用该工艺得到的组合物制备成可接受的药物剂型，能够明显的改善利格列汀的溶出度。

Drugs covered by this patent

Patent Metadata

Patent number
CN105496970A
Jurisdiction
CN
Classification
—
Expires
2016-04-20
Drug substance claim
No
Drug product claim
No
Assignee
BEIJING HUAXI PHARM Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.